Eastman Kodak's unlikely deal with the federal government to dive into drug manufacturing has raised eyebrows—not only for the size of the loan itself but Kodak's lack of experience. Now, with investigations mounting, the U.S. is pumping the brakes.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,